Navigation Links
Heat shock proteins are co-opted for cancer
Date:9/20/2007

CAMBRIDGE, Mass. (Sept. 20, 2007) A Jekyll-Hyde mechanism that both protects healthy cells and enables cancer cells could be the basis for new cancer-fighting drugs.

Scientists in the laboratory of Whitehead Member Susan Lindquist have discovered that a certain transcription factora protein that binds to specific areas of the genome and acts to switch genes on and offknown to aid in handling stresses also facilitates the survival of cancer cells.

According to the study, which appears online in Cell on Sept. 20, this transcription factor may be the basis for powerful new ways to fight cancer.

The transcription factor is the master regulator of cells protective heat-shock responsea complex and multifaceted defense system that kicks in when an organism is exposed to increased temperature, infection, toxins or other stresses. The heat-shock response is thought to have existed for more than a billion years and is found in organisms from bacteria to fruit flies to humans.

Heat-shock transcription factors turn on genes for helpful chaperone proteins that help keep proteins from going bad. If proteins form unhealthy clumps, heat-shock proteins (HSPs) pull them apart. If proteins misfold, HSPs help them refold. If the errant proteins are too far gone, HSPs ship them off to be destroyed.

Postdoctoral associate Chengkai Dai and his colleagues looked at the role of heat-shock factor 1 (HSF1), the master regulator of the heat-shock response, in enabling normal cells to turn into cancer cells.

This work provides the first direct evidence of an important role for HSF1 in helping cells to undergo a malignant transformation, says co-author Luke Whitesell, a research scientist in the Lindquist lab.

While the transcription factor does not itself cause the transformation of a normal cell into a cancer cell, it orchestrates a network of core functions in the cancer cells that govern their proliferation, survival,
'/>"/>

Contact: Eric Bender
bender@wi.mit.edu
617-258-9183
Whitehead Institute for Biomedical Research
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Shock it to Heal!!
2. Aprotinin in the treatment of hemorrhagic shock trauma patients
3. New Implantable Cardioverter Defibrillators to avoid unnecessary shocks
4. Shocked out of drugs?
5. Shock Wave Therapy Increase The Risk Of Diabetes
6. Health Experts Shocked As 11-year-old Girl To Be UKs Youngest Mother
7. Cardiogenic Shock is the Leading Cause of Death for Heart Attack Patients
8. Radioprotective effect of Heat Shock Proteins
9. New Study Finds On/Off Switch for Septic Shock
10. Are call centers turning a deaf ear to potential acoustic shocks?
11. Hong Kong - HIV Test Shock Sparks Warning
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2008)... -- Integrated Medical,Systems, Inc., a medical te...rated products for critical care, announced today .... Food and Drug Administration (FDA) to market,its...U)., "FDA clearance of the MedEx 1000 is a major ...emonstrate the economic and clinical value of,inte...
(Date:10/13/2008)...ly life, survey shows, PORTLAND, Ore., Oct. 13 /P...ers of people living with psoriasis say the diseas...g to a National Psoriasis,Foundation 2008 survey r...h psoriasis and psoriatic arthritis,also revealed ...hapes their,feelings about themselves and affects ...
(Date:10/13/2008)...tes and Washington, D.C., WASHINGTON, Oct. 13 /PR...ay announced a new course. Coping With Deployments...s now available. The course, offered free of,charg...ty, Reserve and,National Guard forces, as well as ... is offered in sixteen states (Ala., Ark., Calif.,...
(Date:10/13/2008)...ws Three Women - Doctors, Working M...sk Babies in Their OB/GYN Practice -, SILVER SPRI...is going,back into the delivery room with the anti...VER ME. The breakout series follows the careers an... and Alane Park -- best,friends who became partner...
Breaking Medicine News(10 mins):Health News:Integrated Medical Systems Receives FDA Clearance for World's First 'Suitcase' Intensive Care Unit 2Health News:Integrated Medical Systems Receives FDA Clearance for World's First 'Suitcase' Intensive Care Unit 3Health News:National Psoriasis Foundation Releases 2008 Study Results 2Health News:American Red Cross Offering Free Class to Help Military Families Cope With the Stress of Deployments 2Health News:Discovery Health is Expecting! Season Two of DELIVER ME is Due on Tuesday, November 11 at 10 PM ET/PT 2Health News:Discovery Health is Expecting! Season Two of DELIVER ME is Due on Tuesday, November 11 at 10 PM ET/PT 3
...llapsed on a family in Karawal Nagar area of north...n and two adults and injuring four others on Satur... the wall of a school building, which had been con...uty commissioner of police R.L Meena said that the...
...inst cancer focusing at the molecular and genetic ...cerous cells is coming under increasing scrutiny./...na at Chapel Hill have demonstrated that these sup...the ultimate development and aggressiveness of can...
... University of Michigan and the Mayo Clinic say th...t not be very effective in women who inherit a com...gene has the ability to influence the levels of a ... tamoxifen against breast cancer. The study which ...
...are encouraging stereotype body images among their...he Florida State University. Even three year olds ...encouraged to eat well and grow physically,// whil...others were of the opinion that their daughters at...
Other Medicine News:Health News:Cancer Cells Trigger Supporting Cells to Turn Cancerous 2
(Date:10/12/2008)...GTON, Oct. 12 /- Boston,Sci...results from an analysis,of nearly 7,500 patients ...e designed to confirm the performance of the TAXUS... System in real-world practice. The,two-year poole...clinical,restenosis in patients with diabetes as e...
(Date:10/10/2008)...- Boston Scientific,Corpora... the Company,s major,events and press announcement...) twentieth annual Transcatheter Cardiovascular Th...from October 12 to 17 in Washington, D.C., Boston...ety and,efficacy data on its TAXUS(R) Express2(TM)...
(Date:10/9/2008)...s Expected in November 2008, BOTHELL, Wash., Oct....mex: DDD ) announced today the completion of pati...ee pivotal trials to evaluate the safety and,effic... (ER) ibuprofen for,the over-the-counter (OTC) mar...s from this pivotal trial in November 2008. Ibupro...
(Date:10/8/2008)...nform Treatments for Spinal Cord, Other Nerve,Inju...re/ -- A protein that enables,nerve cells to commu...ling,the developing nervous system. Research into ... among nerve cells may provide a basis for eventua...heir nervous system,including spinal cord injury....
Breaking Medicine Technology:TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 2Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 3Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 4Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 5Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 6SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3Protein Shown to Play a Key Role in Normal Development of Nervous System 2Protein Shown to Play a Key Role in Normal Development of Nervous System 3Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA 2172 1Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA 2172 2Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA 2172 3Neurocrine Biosciences Announces Conference Call and Webcast to Provide Indiplon Update 2170 1TriWest Contributes 2475 000 to Agencies Supporting California Guardsmen 8177 1TriWest Contributes 2475 000 to Agencies Supporting California Guardsmen 8177 2TriWest Contributes 2475 000 to Agencies Supporting California Guardsmen 8177 3Vanda Presents Phase III Iloperidone Efficacy Data 1052 1Vanda Presents Phase III Iloperidone Efficacy Data 1052 2Vanda Presents Phase III Iloperidone Efficacy Data 1052 3Vanda Presents Phase III Iloperidone Efficacy Data 1052 4
...s of Phase 2 Clinical Data Published at the Americ...g, CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -...ings from its Phase II,multi-center clinical stud...thetic anthracycline currently in development,for ...dings,indicate favorable interim results in terms ...
...s in Patients With Follicular Lymphoma Reported,To... 2007 /PRNewswire/ -- GlaxoSmithKline plc,announce...ial of a,single one-week course of frontline treat...umomab and Iodine I-131 Tositumomab) in,76 patient...gkin,s,lymphoma (NHL). This regimen was found to i...
Other Medicine Technology:Pharmion's Amrubicin Shows Encouraging Results Compared to Standard,of Care in Second Line Treatment of Small Cell Lung Cancer 2Pharmion's Amrubicin Shows Encouraging Results Compared to Standard,of Care in Second Line Treatment of Small Cell Lung Cancer 3Pharmion's Amrubicin Shows Encouraging Results Compared to Standard,of Care in Second Line Treatment of Small Cell Lung Cancer 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 28-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 38-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 58-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 7
...ts make us a leader in this field. With standard a...y laboratory, our Infectious Disease ELISA product...sistency. Our Infectious Disease ELISA menu includ...erological assays including ToRCH, EBV, H. pylori ...
...ts make us a leader in this field. With standard a...y laboratory, our Infectious Disease ELISA product...sistency. Our Infectious Disease ELISA menu includ...erological assays including ToRCH, EBV, H. pylori ...
...ts make us a leader in this field. With standard a...y laboratory, our Infectious Disease ELISA product...sistency. Our Infectious Disease ELISA menu includ...erological assays including ToRCH, EBV, H. pylori ...
...ts make us a leader in this field. With standard a...y laboratory, our Infectious Disease ELISA product...sistency. Our Infectious Disease ELISA menu includ...erological assays including ToRCH, EBV, H. pylori ...
Medicine Products: